‘California sober’? Cannabis may help limit alcohol consumption, study shows
The first randomized controlled trial of the "California sober" approach suggests marijuana may indeed lessen alcohol consumption.
STAT+: Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharma
Novo Nordisk's $199 Ozempic deal shows what telehealth platforms can do for pharma
STAT+: A revelatory profile of RFK Jr.
This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.
STAT+: Smartwatches that detect A-fib are now common. Are they accurate?
In this edition of STAT's Health Tech newsletter: the accuracy of a-fib detections by smartwatches, a digital health intervention for truckers, and more.
Judge approves opioid settlement for Purdue Pharma and Sackler family members who own the company
A federal bankruptcy court judge on Tuesday formally approved OxyContin maker Purdue Pharma’s plan to settle thousands of lawsuits over the harms of opioids.
STAT+: FDA’s stronger warning on Sarepta gene therapy raises new questions about heart risk
Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne muscular dystrophy. What happens next?
STAT+: Vaccine makers have reason for alarm in proposals to reformulate shots
Plus more biotech news, brought to you by The Readout newsletter
STAT+: Pharmalittle: We’re reading about warnings from vaccine makers, the U.K. standoff with pharma, and more
U.S. health authorities are considering how they might discourage or even ban vaccines that rely on a common ingredient to boost their effectiveness
A case study on cravings and a GLP-1
And more health news from the Morning Rounds newsletter
STAT+: Trump administration touts moves to provide HIV prevention drug, but refuses to include South Africa
The US has started to provide doses of a Gilead HIV prevention drug to low-income countries, but the program will not include South Africa, officials said.